Value Investors: 1 Healthcare Stock Set to Rise

Profound Medical Corp. (TSX:PRN) owns technology that offers clinicians and appropriate patients a better alternative to traditional surgical or radiation therapies.

| More on:
Pills spilling out of a prescription pot

Image source: Getty Images.

Profound Medical (TSX:PRN) is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue utilizing the company’s platform technologies. The company’s lead product, the TULSA-PRO system, combines real-time magnetic resonance imaging (MRI), robotically driven thermal ultrasound, and closed-loop temperature feedback control to ablate physician defined region of malignant of benign prostate tissue.

Innovative products

The TULSA-PRO system has shown in clinical and commercial settings to be an effective tool for physicians who are treating prostate diseases, including cancer. In August 2019, the TULSA-PRO system received Food and Drug Administration (FDA) clearance as a Class II device in the United States for thermal ablation of prescribed prostate tissue. The TULSA-PRO system was also approved by Health Canada in November 2019.

In addition, the company’s sonalleve system helps in the treatment of uterine fibroids and palliative pain relief associated with metastases in bone and is also approved in China for non-invasive treatment of uterine fibroids. In November 2020, the sonalleve system also received humanitarian device exemption (HDE) approval from the FDA for treatment of osteoid osteoma.

The company’s systems are designed to be used with MRI scanners and are currently compatible with certain MRI scanners. To date, the company has primarily generated revenues from the commercialization of Profound’s systems in Asia and from the introduction of TULSA in the United States.

Growth by strategic acquisitions

The company continues to pursue additional regulatory approvals in international jurisdictions and invests in research and development and in clinical studies designed to increase the body of evidence necessary to support customer coverage and reimbursement by third-party payors. This includes government programs and private health insurance plans in order to increase commercial adoption of Profound’s products.

Profound considers synergistic strategic acquisitions to expand the applications of platform technology to expand the company’s commercial footprint. The company’s business model in the U.S. is based primarily upon recurring revenues. Profound gets paid on a per-patient-treated basis for the use of the company’s technology, disposables, and services that are designed to help practices come up to speed on productive use of the TULSA technology upon installation.

Robust business model

In other international markets, Profound continues to deploy a business model that consists of two components, including sales of durable goods and one-time use disposable for each patient treated. The company’s financial strategy to date has been to raise sufficient funds through securities offerings and bank financings to fund specific programs within a focused budget.

Prostate cancer is one of the most common types of cancer affecting men. The annual incidence of newly diagnosed cases in 2021 is estimated to reach 248,530 in the U.S., according to the American Cancer Society, and in 2018 there were approximately 450,000 newly diagnosed cases of prostate cancer in Europe, according to the International Agency for Research on Cancer.

Overall, Profound’s technology offers clinicians and appropriate patients a better alternative to traditional surgical or radiation therapies, with respect to clinical outcomes, side effects and recovery time. This should lead to a higher stock price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Nikhil Kumar has no position in any of the stocks mentioned.

More on Investing

Man considering whether to sell or buy
Bank Stocks

BNS Stock: Buy, Sell, or Hold?

Bank of Nova Scotia is up 15% from the 12-month low. Are more gains on the way?

Read more »

Super sized rock trucks take a load of platinum rich rock into the crusher.
Metals and Mining Stocks

Is Newmont Mining Stock a Good Buy Right Now?

Shares of Newmont Mining are down almost 60% from all-time highs, making the gold stock a top choice for value…

Read more »

Growth from coins
Tech Stocks

2 Canadian Growth Stocks to Buy and 1 to Sell

The recent volatility in the stock market has created all kinds of opportunities for long-term investors.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Wednesday, February 21

The Federal Open Market Committee’s meeting minutes and more corporate results are likely to keep TSX stocks volatile today.

Read more »

Retirement
Investing

Got $5,000? Buy and Hold These 3 Value Stocks for Years

Given their solid underlying businesses, healthy growth prospects, and attractive valuation, I am bullish on these three value stocks.

Read more »

money cash dividends
Stocks for Beginners

Got $1,000 to Invest in Stocks? Put It in This Index Fund

This low-cost beginner-friendly ETF is a great way to invest $1,000.

Read more »

Overhead shot of young adults using technology at a table
Tech Stocks

3 Cheap Tech Stocks to Buy Right Now

Given their long-term growth prospects and discounted stock prices, I am bullish on these tech stocks.

Read more »

money cash dividends
Dividend Stocks

Have $500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Right Now

Want some absurdly cheap stocks for your portfolio? Here are two options trading at a huge discount right now.

Read more »